A Novel Series of Highly Potent Benzimidazole-Based Microsomal Triglyceride Transfer Protein Inhibitors
- 21 February 2001
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 44 (6) , 851-856
- https://doi.org/10.1021/jm000494a
Abstract
A series of benzimidazole-based analogues of the potent MTP inhibitor BMS-201038 were discovered. Incorporation of an unsubstituted benzimidazole moiety in place of a piperidine group afforded potent inhibitors of MTP in vitro which were weakly active in vivo. Appropriate substitution on the benzimidazole ring, especially with small alkyl groups, led to dramatic increases in potency, both in a cellular assay of apoB secretion and especially in animal models of cholesterol lowering. The most potent in this series, 3g (BMS-212122), was significantly more potent than BMS-201038 in reducing plasma lipids (cholesterol, VLDL/LDL, TG) in both hamsters and cynomolgus monkeys.Keywords
This publication has 5 references indexed in Scilit:
- Drug Treatment of Lipid DisordersNew England Journal of Medicine, 1999
- An MTP Inhibitor That Normalizes Atherogenic Lipoprotein Levels in WHHL RabbitsScience, 1998
- Trends in the Incidence of Myocardial Infarction and in Mortality Due to Coronary Heart Disease, 1987 to 1994New England Journal of Medicine, 1998
- Effects of Simvastatin on Plasma Lipoprotein Concentrations and Very-Low-Density Lipoprotein Secretion in the Rat.Journal of Clinical Biochemistry and Nutrition, 1995
- Synthesis of Mutagenic Methyl- and Phenyl-substituted 2-Amino-3H-imidazo[4,5-f]quinoxalines via 2,1,3-Benzoselenadiazoles.Acta Chemica Scandinavica, 1993